Dear Dr. Roach: Why doesn’t rheumatoid arthritis have any medicines to help treat it? — S.S.K.

Answer: Rheumatoid arthritis is relatively common (as much as 1% of the population, with women twice as likely to be affected than men), but it’s a much less common form of arthritis than osteoarthritis, which affects as much as 40% to 50% of an older population. However, rheumatoid arthritis is much more feared because it can be destructive to the joints. It can also affect other parts of the body besides the joints, especially the heart, lungs, blood vessels and skin.

When I underwent training, I saw many patients with terrible deformities of their hands, but that is much less common now because there are many new and effective treatments for rheumatoid arthritis.

The typical symptoms of rheumatoid arthritis begin slowly, with joint pain and stiffness, especially in the morning, that might be mistaken for the more-common osteoarthritis. However, the pain from rheumatoid arthritis in the morning, or after a prolonged period of not moving, lasts much longer (usually over an hour) than osteoarthritis (usually under half an hour).

Smaller joints, such as those in the fingers and wrists, are usually the earliest affected. These symptoms shouldn’t be ignored.

Early use of drugs to get RA under control (these are often called DMARDs, disease-modifying antirheumatic drugs) has become the standard of care. Methotrexate is probably the most common drug rheumatologists initially prescribe, but hydroxychloroquine is also frequently used.

Anti-inflammatory drugs, including NSAIDs like ibuprofen as well as steroids like prednisone, are often used at first to get symptoms under control while the DMARDs start working, which may take weeks or months. Once the disease is under control, prednisone-type drugs are stopped entirely or reduced as much as possible to avoid the many long-term adverse effects of these drugs.

There are a wide range of biological therapies that are used in people who do not respond to this treatment. Many of these drugs are monoclonal antibodies working against certain cellular triggers for rheumatoid arthritis.